Thus, BC patients at low risk of metastasis can avoid the need for toxic and costly therapies, while BC patients at high risk of metastasis can undergo a more aggressive system therapy such as a more intense chemotherapy or aggressive targeted therapy for every Her‐2 positive patient and a more intense follow‐up scheme. This evidence concerns the gene ERBB2 and breast cancer.